Investing.com - West Pharmaceutical Services (NYSE: WST) reported third quarter EPS of $1.85, $0.35 better than the analyst estimate of $1.50. Revenue for the quarter came in at $746.9M versus the consensus estimate of $709.3M.
Guidance
West Pharmaceutical Services sees FY 2024 EPS of $6.55-$6.75 versus the analyst consensus of $6.41.
West Pharmaceutical Services sees FY 2024 revenue of $2.88B-$2.91B versus the analyst consensus of $2.87B.
West Pharmaceutical Services's stock price closed at $286.44. It is up 0.59% in the last 3 months and down -19.99% in the last 12 months.
West Pharmaceutical Services saw 0 positive EPS revisions and 8 negative EPS revisions in the last 90 days. See West Pharmaceutical Services's stock price’s past reactions to earnings here.
According to InvestingPro, West Pharmaceutical Services's Financial Health score is "good performance".
Check out West Pharmaceutical Services's recent earnings performance, and West Pharmaceutical Services's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar